© 2026 Azenta, Inc. • All rights reserved Safe Harbor Statement Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding future financial performance including our fiscal year 2026 guidance, business trends, market demand, operational initiatives, strategic priorities, and other expectations or forecasts. These statements are based ...

Azenta Investor Day 2025 Summary Company Overview - **Company**: Azenta (NasdaqGS:AZTA) - **Industry**: Life Sciences Tools - **Market Position**: Category leader in niche product lines with a $6 billion addressable market [6][9][25] Key Points and Arguments Strategic Outlook - **Top-Line Growth**: Azenta aims to outperform the market with significant top-line growth opportunities [5] - **Margin Expansion**: There is potential for margin expansion independent of growth [5] - **Capital Deployment**: The company has a strong balance sheet to support M&A and growth investments [5][22] - **Recurring Revenue**: Approximately 55% of revenue is recurring, indicating a stable income stream [9] Market Dynamics - **Research Spending**: $350 billion is spent annually in research across various sectors, with 50% of that being outsourced [7][8] - **Sample Management**: There are 24 billion samples requiring cold storage and automation, with 50% of FDA therapeutics needing such support [9] - **Customer Base**: Azenta serves 14,000 customers globally, including top pharmaceutical and biotech companies [9][10] Operational Excellence - **Decentralization**: The company has shifted to a decentralized organization with accountable general managers [10] - **Azenta Business System (ABS)**: A cultural shift towards operational excellence, focusing on lean manufacturing and efficiency [15][36] - **Performance Metrics**: Complaints decreased by 55%, and on-time delivery improved by 30% [18] Growth Initiatives - **BioRepositories**: Plans to scale off-site sample storage solutions to manage 100 million samples in four years [39] - **Automation**: Continued investment in automated solutions to enhance productivity [19][40] - **Regionalization**: Gene synthesis operations will be expanded to the U.S. and Western Europe [56] Financial Outlook - **Cash Generation**: Expected to generate $250 million in cash over the next few years, with a goal of doubling EBITDA [6][25] - **Share Buyback**: A $250 million share buyback program has been authorized [22] GENEWIZ Business Segment - **Unique Position**: GENEWIZ is a "category of one" with expertise in both sequencing and synthesis solutions [46] - **Market Share**: Currently holds less than 10% of a $3 billion addressable market, indicating significant growth potential [54] - **Customer Loyalty**: Over 70% of revenue comes from returning customers, highlighting strong customer relationships [51] Investment Focus - **Technology and Innovation**: Investments will be made in cutting-edge technologies to enhance service offerings [48][56] - **Digital Transformation**: E-commerce solutions will be introduced to improve customer interactions [57] Conclusion - **Strong Foundation**: Azenta is positioned for above-market growth with a robust balance sheet and a unique product ecosystem [25] - **Commitment to Customers**: The company emphasizes a partnership approach with customers to drive innovation and efficiency [14][61] This summary encapsulates the strategic direction, market dynamics, operational improvements, and financial outlook of Azenta as discussed during the Investor Day 2025.

Company Overview and Strategy - Azenta is uniquely positioned for strong top-line growth, margin expansion, and inorganic growth opportunities[15] - The company estimates a current serviceable addressable market (SAM) of approximately $6 billion across SMS and Multiomics[18] - Azenta's FY25 revenue was $594 million, with approximately 55% recurring revenue and 3% organic year-over-year growth[26] Sample Management Solutions (SMS) - SMS FY'25 revenue was approximately $325 million, with approximately 50% recurring revenue[85] - The SMS business has experienced a 15%+ CAGR in sample storage growth from FY'15 to FY'25[85] - The company estimates SMS has approximately 11% market share of a $3 billion serviceable addressable market[18, 88] Multiomics (GENEWIZ) - Multiomics (GENEWIZ) FY'25 revenue was approximately $269 million, with over 70% of revenue from returning customers[132] - The company estimates Multiomics has approximately 9% market share of a $3 billion serviceable addressable market[18, 137] - GENEWIZ has sequenced 15 petabytes (PB) of data and synthesized 425 million nucleotides[128] Financial Targets and Capital Allocation - The company is targeting cumulative free cash flow generation of $200 million - $250 million from FY2026 to FY2028[172] - Azenta has a $250 million share repurchase authorization[61] - The company is introducing 2028 organic financial targets including $700 million - $750 million in revenue, 6% - 8% CAGR, 70% recurring revenue, $120 million - $150 million adjusted EBITDA, and 18% - 20% adjusted EBITDA margin[186]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $159 million, up 6% year-over-year, and up 4% organically, with full-year revenue at $594 million, reflecting a 4% increase on a reported basis and 3% organic growth [14][15] - Non-GAAP EPS for Q4 was $0.21, and $0.51 for the full year, with adjusted EBITDA margin at 13% for Q4 and 11.2% for the full year, representing an expansion of approximately 230 basis points in Q4 and 310 basis points for the full year [14][15] - Free cash flow for the full year was $38 million, a notable improvement of $26 million year-over-year, with $546 million in cash, cash equivalents, and marketable securities at year-end [15][20] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $86 million for Q4, up 2% reported and flat organically, with a non-GAAP gross margin of 49.3%, up 180 basis points year-over-year [17][18] - Multi-Omix segment delivered record revenue of $73 million in Q4, representing 11% growth on a reported basis and 10% organic growth, driven by a 50% year-over-year increase in sequencing volume [18][19] Market Data and Key Metrics Changes - The macro environment remains volatile, with softer academic and NIH funding impacting growth, particularly in the U.S. market [9][10] - The company anticipates organic revenue growth of 3%-5% for fiscal 2026, with expectations of a decline of approximately 1%-2% in Q1 due to capital expenditure slowdowns and government shutdown impacts [21][60] Company Strategy and Development Direction - The company has implemented the Azenta Business System (ABS) to enhance operational efficiency and accountability, focusing on driving productivity, organic growth, and targeted M&A [8][10] - Strategic priorities include embedding ABS deeper across the organization, optimizing capital deployment, and continuing to deliver core growth and margin expansion [11][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and highlighted opportunities arising from customers consolidating partners and investing in automation [9][10] - The company is well-positioned for fiscal 2026, with a focus on operational excellence and a strong balance sheet to support growth initiatives [11][22] Other Important Information - The results exclude B Medical Systems, which is treated as discontinued operations, with an additional non-cash loss of $4 million recorded in Q4 [13] - The company plans to host an Investor Day to outline its multi-year growth strategy and capital deployment priorities [11][21] Q&A Session Summary Question: Guidance on growth expectations and market conditions - Management noted that the market is expected to grow at 1-2%, with capital expenditure slowdowns impacting growth, particularly in the U.S. [25][26] Question: Update on SMS growth and backlog - Confidence in mid-single-digit growth for SMS is supported by a strong backlog and recent investments in commercial initiatives [29][30] Question: Insights on macroeconomic trends affecting customer bases - Management highlighted strength in pharma spending, with some projects being put on hold but showing signs of recovery [38][40] Question: Expectations for M&A activity - The company is focused on tuck-in acquisitions to expand its core business, particularly in SRS and automated solutions [69][70]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $159 million, up 6% year-over-year and up 4% organically, with full-year revenue at $594 million, reflecting a 4% increase on a reported basis and 3% organically [12][14] - Non-GAAP EPS for Q4 was $0.21, and for the full year, it was $0.51, with adjusted EBITDA margin at 13% for Q4 and 11.2% for the full year, representing an expansion of approximately 230 basis points in Q4 and 310 basis points for the full year [13][14] - Free cash flow for the full year improved by $26 million year-over-year, totaling $38 million, with $546 million in cash, cash equivalents, and marketable securities at year-end [14][19] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $86 million for Q4, up 2% reported and flat organically, with a non-GAAP gross margin of 49.3%, up 180 basis points year-over-year [16] - Multi-Omix segment achieved record revenue of $73 million in Q4, representing 11% growth on a reported basis and 10% organic growth, driven by a 50% year-over-year increase in sequencing volume [17] - Overall, Multi-Omix gross margin for Q4 was 43.7%, down 260 basis points year-over-year, primarily due to product mix and lower volume in certain areas [18] Market Data and Key Metrics Changes - The macro environment remains volatile, with softer academic and NIH funding impacting growth, particularly in the U.S. market [8][9] - The company anticipates organic revenue growth of 3%-5% for fiscal 2026, with Multi-Omix expected to deliver low single-digit growth and SMS contributing mid-single-digit growth [20][21] Company Strategy and Development Direction - The company has implemented the Azenta Business System (ABS) to enhance operational efficiency and accountability, focusing on driving productivity, organic growth, and targeted M&A [6][7] - The strategic focus includes reinvesting savings into innovation, sales, marketing, and product management, with a commitment to operational excellence and value creation [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and highlighted opportunities arising from customer consolidation and outsourcing trends [9][10] - The company is entering fiscal 2026 from a position of strength, with a clear focus on core growth and margin expansion, despite anticipated challenges in the first half of the year [10][21] Other Important Information - The results exclude B Medical Systems, which is treated as discontinued operations, with an additional non-cash loss of $4 million recorded in Q4 [11] - The company plans to host an Investor Day to outline its multi-year growth strategy and capital deployment priorities [10][21] Q&A Session Summary Question: Guidance on growth expectations and market conditions - Management noted that the macroeconomic slowdown and capital expenditure constraints are impacting growth, particularly in the U.S., with expectations of a 1-2% market growth [24][25] Question: Update on SMS growth and backlog - Confidence in mid-single-digit growth for SMS is supported by a strong backlog and recent commercial investments [29][30] Question: Insights on customer spending trends - Management highlighted strength in pharma spending, with some projects being reactivated post-restructuring [36] Question: Clarification on multi-omics growth expectations - Multi-Omix is expected to normalize to mid-single-digit growth due to price and volume adjustments [38] Question: M&A strategy and focus areas - The company is looking at tuck-in acquisitions to expand its core business, particularly in SRS and automated solutions [63][64]

Conference Call Fiscal Fourth Quarter and Full Year 2025 Financial Results November 21, 2025 © 2025 Azenta, Inc. • All rights reserved 1 1 Safe Harbor Statement "Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward- looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, f ...

Core Viewpoint - Azenta, Inc. reported a transformative fiscal year 2025 with significant revenue growth and margin expansion, positioning the company for continued growth in fiscal 2026 [3][5]. Financial Performance - For Q4 2025, revenue from continuing operations was $159 million, a 6% increase year-over-year, with organic growth of 4% [2][6]. - Full year revenue for fiscal 2025 reached $594 million, up 4% year-over-year, with organic revenue growth of 3% [2][6]. - Adjusted EBITDA for Q4 2025 was $21 million, representing a 29% increase from the previous year, with an adjusted EBITDA margin of 13.0% [2][6]. - The company achieved a diluted EPS from continuing operations of $1.11 for Q4 2025, compared to a loss of $0.04 in the same quarter last year [2][6]. Segment Performance - Sample Management Solutions generated $86 million in revenue for Q4 2025, a 2% increase year-over-year, while Multiomics revenue was $73 million, up 11% year-over-year [2][6]. - For the full year, Sample Management Solutions revenue was $325 million, a 2% increase, and Multiomics revenue was $269 million, up 6% year-over-year [2][6]. Management Insights - The CEO highlighted the company's streamlined structure and focus on customer needs, projecting core growth of 3% to 5% and approximately 300 basis points of adjusted EBITDA margin expansion for fiscal 2026 [3][5]. - The company emphasized improvements in quality, delivery, and productivity as key drivers of its recent success [3]. Cash and Liquidity - As of September 30, 2025, Azenta had a total balance of cash, cash equivalents, restricted cash, and marketable securities amounting to $546 million [2][6]. Guidance - Azenta expects organic revenue growth for fiscal 2026 to be in the range of 3% to 5%, along with an anticipated adjusted EBITDA margin expansion of approximately 300 basis points [5][6].

Financial Data and Key Metrics Changes - Organic revenue grew by 6% year over year, with adjusted EBITDA margin expanding by 400 basis points [7][26][28] - Total revenue for the second quarter was $143 million, reflecting a 5% year-over-year increase on a reported basis and 6% on an organic basis [27][29] - Non-GAAP EPS for the quarter was $0.05, with adjusted EBITDA margin at 10% [28][29] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $80 million, up 8% year over year, driven by strong performance in sample repository solutions and core products [30] - Multiomics revenue was $64 million, with a growth of 2% on a reported basis and 3% on an organic basis, primarily driven by next-generation sequencing, which grew 20% year over year [31][32] Market Data and Key Metrics Changes - North America experienced a general slowdown, with an 18% year-over-year decline in Sanger sequencing, while China showed strength with 5% organic revenue growth [34][32] - The company noted a decline in gene synthesis revenue by 10% year over year, attributed to a difficult comparison against a strong prior year [33] Company Strategy and Development Direction - The company is focused on operational excellence and reducing complexity through the Azenta Business System, which aims to enhance problem-solving capabilities and align with strategic goals [12][13] - There is an emphasis on potential tuck-in acquisitions to accelerate revenue growth and margin expansion, alongside investments in digital capabilities [11][12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertain macro environment, including NIH funding cuts and geopolitical tensions, but expressed confidence in the company's ability to counteract these challenges [9][10] - The company reaffirmed its full-year guidance for organic revenue growth between 3% and 5% and adjusted EBITDA margin expansion of 300 basis points [36][37] Other Important Information - The company has $540 million in cash and cash equivalents, with no debt outstanding, positioning it well for potential acquisitions and capital deployment [11][36] - A non-cash loss of $24 million was recorded on assets held for sale related to B Medical Systems, which is now treated as discontinued operations [25] Q&A Session Summary Question: Guidance and Growth Cadence - Management indicated that the guidance remains unchanged despite a 1% impact from NIH funding, with expectations for the second half of the year to align with prior years [41][44] Question: NIH Funding Headwind - The company has implemented countermeasures to mitigate the 1% headwind from NIH funding, with a focus on outsourcing opportunities as less efficient labs may close [52][57] Question: Free Cash Flow and Margins - Free cash flow performance was strong, and the company remains optimistic about achieving its long-term target of $100 million in free cash flow [58][60] Question: Sales Force Structure - The company is early in the rollout of the Azenta Business System and has aligned its sales force regionally to improve performance [65] Question: Gene Synthesis Trends - Management noted a pause in large programs from pharma partners but observed positive trends in bookings for the current quarter [78][80] Question: Capital Deployment Preferences - The company is open to various capital deployment strategies, including M&A and share buybacks, with a focus on long-term shareholder value [84][86]

Financial Performance - Azenta's Q2 2025 revenue reached $143 million, demonstrating a 5% year-over-year (YoY) growth on a reported basis and 6% on an organic basis[10] - The company's Non-GAAP EPS stood at $005[10] - Adjusted EBITDA was reported at 100%, reflecting a 400 bps YoY margin expansion[10,11] - Free cash flow generation amounted to $7 million, inclusive of B Medical[10] Segment Performance - Sample Management Solutions (SMS) experienced an 8% YoY organic growth[10,16] - Multiomics segment saw a 3% YoY organic growth[10,14] - Within SMS, Consumables and Instruments (C&I) showed a significant 22% growth[20] - Next-Generation Sequencing (NGS) within Multiomics grew by 20%, driven by double-digit volume growth[21] Balance Sheet and Cash Flow - The company holds a strong cash balance of $540 million, including B Medical, with no outstanding debt[10] - Cash flow from operations was $14 million[32] Fiscal Year 2025 Guidance - The company anticipates organic revenue growth of 3% to 5% YoY for fiscal year 2025[38] - Expects 300bps of Adjusted EBITDA margin expansion[39]

Core Insights - The company reported a total revenue of $143 million for the quarter ended March 31, 2025, reflecting a 5% increase year-over-year, driven by growth in Sample Management Solutions and Multiomics [2][7] - The diluted EPS from continuing operations was $(0.40), compared to $(0.29) in the same quarter of the previous year, indicating a significant loss [2][24] - The company has a strong cash position with total cash, cash equivalents, and marketable securities amounting to $540 million as of March 31, 2025 [14] Financial Performance - Revenue from continuing operations was $143 million, down 3% from the previous quarter but up 5% year-over-year [2][7] - Organic revenue growth was 6% year-over-year, with Sample Management Solutions revenue at $80 million, up 8% year-over-year [2][7] - Adjusted EBITDA for continuing operations was $14 million, with an adjusted EBITDA margin of 10.0%, an improvement of 400 basis points year-over-year [2][7] Management Commentary - The CEO highlighted the company's strong performance amidst a challenging macroeconomic environment, emphasizing the resilience of the portfolio and the commitment of the teams [3] - The management expressed confidence in the company's positioning and disciplined operations while navigating uncertainties [3] Cash Flow and Guidance - Operating cash flow for the quarter was $14 million, with capital expenditures of $7 million, resulting in free cash flow of $7 million [14] - The company reiterated its revenue guidance for fiscal year 2025, expecting total organic revenue growth in the range of 3% to 5% compared to fiscal 2024 [14]